Taiwan Liposome Ltd (TLC) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access TLC Annual Income Statement →
Reviewing income statement figures over time helps illustrate how Taiwan Liposome Ltd generates earnings and manages operating expenses.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2020)
Q4 2020
0 0 0 (Dec 31 2019)
Revenues
Total Revenue3.63
Costs & Expenses
Gross Profit3.63
Research and Development Expense-34.46
Other Operating Expense / -Income111.74
Total operating costs including COS38.64
Operating income / -loss-35.01
Net Interest Expense / -Income0.00
Other loss / -income-0.03
Total costs & expenses38.61
Income & Taxes
Income / -loss before income taxes-34.98
Income taxes expenses / -benefit0.04
Income after income taxes-35.02
Net income / -loss of other equity0.00
Income / -loss from continuing operations-35.02
Non-controlling interests-0.06
Net income / -loss-35.02
Income / -loss to shareholder-34.95
EBIT-34.98
EBITD-33.09
EBITDA-32.98
Earnings Per Share
Basic EPS (excl. extra items)-0.44
Basic Net EPS-0.44
Basic shares outstanding (Mill. of Units)79.44
Diluted Net EPS-0.44
Diluted average shares (Mill. of Units)79.44
4 historic quarters locked

Sign in to unlock the full Taiwan Liposome Ltd income statement history.

About TLC Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.